Skills
- Richard Begent
Gastrointestinal cancer, antibody targeted therapy & imaging biomedical informatics
- Chris Boshoff
Sarcoma, head and neck cancer, Kaposi's sarcoma, tumour virology, molecular oncology
- Stephen Bown
Laser therapy
- John Bridgewater
Gastrointestinal cancer, translational research linked to Phase III clinical trials
- Martyn Caplin
Neuroendocrine cancer
- David Chao
Melanoma, renal cancer, biological therapy
- Kerry Chester
Protein and antibody engineering, proteomics by mass spectroscopy, novel therapies
- Mary Collins
Gene therapy
- Peter Ell
Nuclear medicine, novel imaging for diagnosis and response assessment in cancer patients
- Alan Green
Medical Physics, SPECT imaging, mathematical modelling
- John Hartley
DNA damage and repair
- Daniel Hochhauser
Gastrointestinal cancer, DNA interacting agents, EGFR
- Ian Jacobs
Gynaecological cancer, ovarian cancer screening
- Jonathan Ledermann
Gynaecological cancer, translational research in clinical trials
- David Linch
Haematology, haematological malignancies
- Laurence Lovat
Oesophageal cancer and Barrett's oesophagus, early diagnosis treatment of pre-malignant disease
- Stephen Mackinnon
Haematology, immunotherapy & stem cell transplantation
- John Masters
Prostate cancer, stem cells, molecular pathology
- Astrid Mayer
Gastrointestinal cancer, antibody targeted therapy & imaging, biomedical informatics
- Tim Meyer
Gastrointestinal cancer, antivascular therapy, cell adhesion molecules
- Antony Michalski
Paediatric cancer
- Sylvia Nagl
Cancer systems science, biomedical Informatics & data modelling
- Marco Novelli
Pathology, novel prognostic markers for diagnosis and prognosis
- Barbara Pedley
Tumour biology, microscopy imaging systems, pre-clinical therapeutics (antibody-targeted therapy & anti-vascular drugs)
- Stephen Pereira
Hepatobiliary cancer, photodynamic therapy, novel prognostic markers
- Michele Saunders
Head and neck cancer, radiotherapy fractionation, Phase I radiation therapy trials
- Susan Short
Neuro-oncology, radiotherapy fractionation, Phase I trials
- Hans Stauss
Cancer immunology, T-cell therapy
- Martin Widschwendter
Gynaecological cancer, epigenetics
- Gareth Williams
Pathology, DNA replication licensing
- Surinder Sharma
Antibody Directed Enzyme Prodrug Therapies (ADEPT), pre-clinical and translational therapeutics, GCLP for clinical PK and PD, immunogenicity of protein therapeutics
- Geoffrey Boxer
Pathology, administration
- Helen MacColl
Co-ordinator/administration
- Carmel Hopkins
Administration